These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8835112)

  • 41. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS.
    Kimura S; Matsuda J; Ikematsu S; Miyazono K; Ito A; Nakahata T; Minamitani M; Shimada K; Shiokawa Y; Takaku F
    AIDS; 1990 Dec; 4(12):1251-5. PubMed ID: 1708265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
    Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
    Calderón EJ; Torres Y; Medrano FJ; Luque F; Larder B; Rey C; Sánchez-Quijano A; Lissen E; Leal M
    Eur J Clin Microbiol Infect Dis; 1995 Jun; 14(6):512-9. PubMed ID: 7588824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine.
    Aweeka FT; Kwong M; Mak M; al-Uzri A; Affrime M; Cutler D; Kahn J; Gambertoglio JG
    J Clin Pharmacol; 1996 Dec; 36(12):1107-13. PubMed ID: 9013366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
    Simberkoff MS; Hartigan PM; Hamilton JD; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM; Hawkes CA; Jensen PC; Kilmas NG; Labriola AM; O'Brien WA; Oster CN; Weinhold KJ; Wray NP; Pazner SB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):142-50. PubMed ID: 8556396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection.
    Thompson KA; Strayer DR; Salvato PD; Thompson CE; Klimas N; Molavi A; Hamill AK; Zheng Z; Ventura D; Carter WA
    Eur J Clin Microbiol Infect Dis; 1996 Jul; 15(7):580-7. PubMed ID: 8874076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor.
    Aweeka FT; Mak M; al-Uzri A; Peter K; Dett C; Franco J; Affrime M; Guerciolini R; Cutler DL; Kahn J
    J Clin Pharmacol; 1995 Sep; 35(9):856-64. PubMed ID: 8786245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.
    Mannucci PM; Gringeri A; Savidge G; Gatenby P; Laurian Y; Pabinger-Fasching I; Martinez-Vazquez JM; Hessey EW; Steel HM
    Br J Haematol; 1994 Jan; 86(1):174-9. PubMed ID: 7912097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
    Koot M; Schellekens PT; Mulder JW; Lange JM; Roos MT; Coutinho RA; Tersmette M; Miedema F
    J Infect Dis; 1993 Sep; 168(3):733-6. PubMed ID: 8102631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
    Bass HZ; Hardy WD; Mitsuyasu RT; Taylor JM; Wang YX; Fischl MA; Spector SA; Richman DD; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1992; 5(3):215-21. PubMed ID: 1346807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
    Gill S; Tang A; Cordery M; Spacey B; Kelly G; Bateman NT; Barlow D
    Genitourin Med; 1991 Feb; 67(1):15-7. PubMed ID: 1680791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: a longitudinal placebo-controlled study.
    Baldeweg T; Riccio M; Gruzelier J; Hawkins D; Burgess A; Irving G; Stygall J; Catt S; Catalan J
    J Neurol Sci; 1995 Oct; 132(2):162-9. PubMed ID: 8543942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: preliminary clinical experience.
    Maggiolo F; Taras A; Pravettoni MG; Leone M; Ingrosso A; Suter F
    Infection; 1997; 25(1):35-8. PubMed ID: 9039536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of CD4+ T cells, HIV disease stage and zidovudine on HIV isolation in Bahia, Brazil.
    Brites C; Pedroso C; Silva N; Johnson WD; Badaró R
    Rev Soc Bras Med Trop; 1996; 29(1):5-9. PubMed ID: 8851208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy.
    Graham NM; Park LP; Piantadosi S; Phair JP; Mellors J; Fahey JL; Saah AJ
    Clin Infect Dis; 1995 Feb; 20(2):352-62. PubMed ID: 7742442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients.
    Medrano FJ; Leal M; Arienti D; Rey C; Zagliani A; Torres Y; Sanchez-Quijano A; Lissen E; Clerici M
    AIDS Res Hum Retroviruses; 1998 Jul; 14(10):835-43. PubMed ID: 9671212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia.
    Clumeck N; Wit SD; Hermans P; Franchioly P; Sommereijns B
    J Nutr Sci Vitaminol (Tokyo); 1992; Spec No():353-6. PubMed ID: 1284305
    [No Abstract]   [Full Text] [Related]  

  • 60. Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.
    Katayama Y; Kojima K; Omoto E; Harada M
    Int J Hematol; 1996 Dec; 65(1):89-92. PubMed ID: 8990630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.